Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

Clinical and Immunohistochemical Characteristics of Thyroid Papillary Cancer with Lateral Neck Lymph Node Metastasis

측경부 림프절 전이를 동반한 갑상선 유두상암의 임상 양상과 면역조직화학적 특성

  • Lee, Seon-Uk (Department of Otorhinolaryngology-Head and Neck Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Jin, Sung-Min (Department of Otorhinolaryngology-Head and Neck Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Sang-Hyuk (Department of Otorhinolaryngology-Head and Neck Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Sohn, Jin-Hee (Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Chae, Seung-Wan (Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Kim, Dong-Hoon (Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 이선욱 (성균관대학교 의과대학 강북삼성병원 이비인후과학교실) ;
  • 진성민 (성균관대학교 의과대학 강북삼성병원 이비인후과학교실) ;
  • 이상혁 (성균관대학교 의과대학 강북삼성병원 이비인후과학교실) ;
  • 손진희 (성균관대학교 의과대학 강북삼성병원 병리학교실) ;
  • 채승완 (성균관대학교 의과대학 강북삼성병원 병리학교실) ;
  • 김동훈 (성균관대학교 의과대학 강북삼성병원 병리학교실)
  • Published : 2011.05.27
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Objectives : Papillary thyroid carcinoma(PTC) frequently metastasize to the regional neck, however, lateral neck lymph node metastasis is less common. The aim of this study is to investigate clinical and immunohistochemical features of PTC with lateral LN metastasis, and determine the predictive factors for lateral LN metastases. Material and Methods : We undertook a retrospective study of 83 patients treated between January 2007 and December 2009 for PTC by thyroidectomy with or without lateral neck dissection. The following criteria were used to study the clinical predictive value of lateral LN. metastases : sex, age, tumor size, multifocality, extracapsular spread(ECS) and lymphovascular emboli. Immunohistochemical staining for VEGF-A, VEGF-C, Bax, Bcl-2, Cyclin D1, Cyclin E, $p27^{kip1}$ and $p57^{kip2}$ was performed, and quantified blindly by three pathologists who had no clinical information of the patients. Immunohistochemical expression was scored as high(>50% of cells stained) or low(0-49%). Results : With use of univariate and multivariate analysis, tumor size(>2cm) and ECS were independent correlates of lateral LN metastasis in PTC. Expression of VEGF-C, Bax, and Cyclin D1 in the PTC with lateral LN metastasis was scored higher than in PTC without lateral LN metastasis(p<0.05). Conclusion : The important risk factors for lateral LN metastasis in PTC are primary tumor size and the presence of ECS. And expression of VEGF-C, Bax and cyclin D1 may be considered of lateral LN metastatic potential in PTC.

Keywords

References

  1. Kebebew E, Clark OH. Differentiated thyroid cancer: "Complete" Rational approach. World J Surg. 2000;24(8):942-951. https://doi.org/10.1007/s002680010165
  2. Caron NR, Clark OH. Papillary thyroid cancer: Surgical management of lymph node metastases. Curr Treat Options Oncol. 2005;6(4):311-322. https://doi.org/10.1007/s11864-005-0035-9
  3. Sivanandan R, Soo KC. Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg. 2001;88(9):1241-1244. https://doi.org/10.1046/j.0007-1323.2001.01843.x
  4. Kupferman ME, Patterson M, Mandel SJ, LiVolsi V, Weber RS. Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130(7):857-860. https://doi.org/10.1001/archotol.130.7.857
  5. Mann B, Buhr HJ. Lymph node dissection in patients with differentiated thyroid carcinoma--who benefits? Langenbecks Arch Surg. 1998;383(5):355-358. https://doi.org/10.1007/s004230050148
  6. Lim YS, Lee JC, Lee YS, Lee BJ, Wang SG, Son SM, et al. Lateral cervical lymph node metastases from papillary thyroid carcinoma: Predictive factors of nodal metastasis. Surgery 2011 Apr 19[Epub ahead of print].
  7. Gulben K, Berberoglu U, Celen O, Mersin HH. Incidental papillary microcarcinoma of the thyroid factors affecting lymph node metastasis. Langenbecks Arch Surg. 2008;393(1):25-29.
  8. Kaptan G, Ugur B, Orhan C, Husnu HM. Incidental papillary microcarinoma of the thyroid factors affecting lymph node metastasis. Langenbecks Arch Surg. 2007;393(1):25-29. https://doi.org/10.1007/s00423-007-0213-2
  9. Lee SJ, Jin SM, Lee SH, Yeo JO, Lee SU, Son JH, et al. Expression of Bcl-2, Bax and p27 in patients with papillary thyroid cancer with or without lymph node metastasis. Korean J Otorhinolaryngol-Head Neck Surg. 2010;53:153-158. https://doi.org/10.3342/kjorl-hns.2010.53.3.153
  10. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties indifferentiated carcinoma of the thyroid. Am J Surg. 1996;172:692-694. https://doi.org/10.1016/S0002-9610(96)00310-8
  11. Park CS, Min JS. Lateral neck mass as the initial manifestation of thyroid carcinoma. Head Neck. 1989;11:410-413. https://doi.org/10.1002/hed.2880110506
  12. Lee JK, Lee DG, Lee JC, Lee BJ, Wang SG. Clinical characteristics of multifocal papillary thyroid carcinoma. Korean J Otorhinolaryngol Head Neck Surg. 2007;50(7):627-631.
  13. Block MA, Hendrick JW. Thyroid carcinoma in children: Aselective operative approach. South Med J. 1971;64:791-797. https://doi.org/10.1097/00007611-197107000-00003
  14. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg. 1991;162:353-356. https://doi.org/10.1016/0002-9610(91)90147-6
  15. Tae K, Jeon SH, Lee HC, Kim KR, Lee HS. Pattern and treatment of papillary thyroid carcinoma with cervical lymph node metastasis. Korean J Otolaryngol Head Neck. 2005;48:1506-1511.
  16. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J pathol. 1997;181:140-145. https://doi.org/10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A
  17. Moore D, Ohene-Fianko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasm: Relationship with p53 and Bcl-2 expression. Histopathology. 1988;32:35-42.
  18. Ito Y, Toshida H, Nakano K, Takamura T, Miya A, Kobayashi K, et al. Bag-1 expression in thyroid neoplasm: Its correction with bcl-2 expression and carcinoma dedifferentiation. Anticancer Res. 2003;23:569-576.
  19. Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC, et al. Bcl-2 and Bax expression in thyroid tumors. Virchows Archiv. 1997;430:125-130. https://doi.org/10.1007/BF01008033
  20. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dorken B, et al. Bax expression in benign and malignant thyroid tumours: Dysregulation of wild-type p53 is associated with a high Bax and p21 expression in thyroid carcinoma. International Journal of Cancer. 2001;92:805-811. https://doi.org/10.1002/ijc.1284
  21. Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kayqusuz I, et al. Expression of Bax, p53 and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol. 2007;28:31-36. https://doi.org/10.1016/j.amjoto.2006.06.008
  22. Upreti M, Lyle CS, Skaug B, Chambers T. Vinblastine-induced apoptosis is mediated by discrete alterations in subcellular location, oligomeric structure, and activation status of specific Bcl-2 family members. Journal of Biological Chemistry. 2006; 281:15941-15950 https://doi.org/10.1074/jbc.M512586200
  23. Wang S, Wuu J, Savas L. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol. 1998;29(11):1304-1309. https://doi.org/10.1016/S0046-8177(98)90262-3
  24. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677. https://doi.org/10.1126/science.274.5293.1672
  25. Pickett CA, Agoff SN, Widman TJ. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: Prognostic implications. Thyroid. 2005;15(5):461-473. https://doi.org/10.1089/thy.2005.15.461
  26. Khoo ML, Beasley NJ, Ezzat S. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(4):1814-1818. https://doi.org/10.1210/jc.87.4.1814
  27. Brzeziński J, Migodziński A, Gosek A, Tazbir J, Deolejus M. et al. Cyclin E expression in papillary thyroid carcinoma: relation to staging. Int J Cancer. 2004;109(1):102-105. https://doi.org/10.1002/ijc.11673
  28. Lohela M, Helotera H, Haiko P, Dumont DJ, Alitalo K. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Am J Pathol. 2008;173:1891-1901. https://doi.org/10.2353/ajpath.2008.080378
  29. Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M, Karpuzoglu G. Clinical importance of vascular endothelial growth factor(VEGF) for papillary thyroid carcinoma. APMIS. 2003; 111(3):439-443. https://doi.org/10.1034/j.1600-0463.2003.t01-1-1110209.x
  30. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor(VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid disease. Int J Exp Pathol. 2007;88(4):271-277. https://doi.org/10.1111/j.1365-2613.2007.00533.x
  31. Dhar DK, Kubota H, Kotoh T. Tumor vascularity predicts recurrence in differentiated thyroid carcinoma. Am J Surg. 1998; 176:442-447. https://doi.org/10.1016/S0002-9610(98)00238-4
  32. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta. 2004;1654:3-12.
  33. Mandriota SJ, Jussila L, Jeltsch M. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumor metastasis. EMBO J. 2001;20:672-682. https://doi.org/10.1093/emboj/20.4.672
  34. Beasley NJ, Prevo R, Banerji S. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 2002;62:1315-1320.